Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value

被引:22
|
作者
Chen, Yixi [1 ]
Guzauskas, Gregory F. [2 ]
Gu, Chengming [1 ]
Wang, Bruce C. M. [2 ,3 ]
Furnback, Wesley E. [3 ]
Xie, Guotong [4 ]
Dong, Peng [1 ]
Garrison, Louis P. [2 ]
机构
[1] Pfizer Investment Co Ltd, Med, Beijing 100010, Peoples R China
[2] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[3] Elysia Grp LLC, New York, NY 10016 USA
[4] IBM Res, Beijing 100010, Peoples R China
来源
JOURNAL OF PERSONALIZED MEDICINE | 2016年 / 6卷 / 04期
关键词
big data; precision health economics; precision medicine;
D O I
10.3390/jpm6040020
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The "big data" era represents an exciting opportunity to utilize powerful new sources of information to reduce clinical and health economic uncertainty on an individual patient level. In turn, health economic outcomes research (HEOR) practices will need to evolve to accommodate individual patient-level HEOR analyses. We propose the concept of "precision HEOR", which utilizes a combination of costs and outcomes derived from big data to inform healthcare decision-making that is tailored to highly specific patient clusters or individuals. To explore this concept, we discuss the current and future roles of HEOR in health sector decision-making, big data and predictive analytics, and several key HEOR contexts in which big data and predictive analytics might transform traditional HEOR into precision HEOR. The guidance document addresses issues related to the transition from traditional to precision HEOR practices, the evaluation of patient similarity analysis and its appropriateness for precision HEOR analysis, and future challenges to precision HEOR adoption. Precision HEOR should make precision medicine more realizable by aiding and adapting healthcare resource allocation. The combined hopes for precision medicine and precision HEOR are that individual patients receive the best possible medical care while overall healthcare costs remain manageable or become more cost-efficient.
引用
收藏
页数:8
相关论文
共 39 条
  • [31] Editorial: Community series in towards precision medicine for immune-mediated disorders: advances in using big data and artificial intelligence to understand heterogeneity in inflammatory responses, volume II
    Zhou, Xu-jie
    Laouar, Yasmina
    Tsoi, Lam C.
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [32] CLINICAL UTILITY INDEX OF ORILISSA® (ELAGOLIX) IN ENDOMETRIOSIS: A PERSONALIZED MEDICINE MODELING APPROACH INFORMED BY HEALTH ECONOMICS & OUTCOMES RESEARCH (HEOR) DATA.
    Shebley, M.
    Winzenborg, I.
    Soliman, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S41 - S41
  • [33] A Primer in Precision Nephrology: Optimizing Outcomes in Kidney Health Through Disease via Data-Driven Medicine (vol 4, pg e544, 2023)
    Jayaraman, Pushkala
    Crouse, Andrew
    Nadkarni, Girish
    Might, Matthew
    KIDNEY360, 2023, 4 (07): : 1010 - 1010
  • [34] Commentary on "Health economics and the value of therapy in Alzheimer's disease." Report from the Alzheimer's Association Research Roundtable on patient-reported outcomes and dementia research
    Frank, Lori B.
    ALZHEIMERS & DEMENTIA, 2007, 3 (03) : 162 - 165
  • [35] Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research's Institute of Nutrition, Metabolism and Diabetes and the US National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases
    Cefalu, William T.
    Andersen, Dana K.
    Arreaza-Rubin, Guillermo
    Pin, Christopher L.
    Sato, Sheryl
    Verchere, C. Bruce
    Woo, Minna
    Rosenblum, Norman D.
    DIABETES CARE, 2022, 45 (01) : 3 - 22
  • [36] Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research's Institute of Nutrition, Metabolism and Diabetes and the US National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases
    Cefalu, William T.
    Andersen, Dana K.
    Arreaza-Rubin, Guillermo
    Pin, Christopher L.
    Sato, Sheryl
    Verchere, C. Bruce
    Woo, Minna
    Rosenblum, Norman D.
    DIABETES, 2022, 71 (01) : 1 - 22
  • [37] Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research's Institute of Nutrition, Metabolism and Diabetes and the US National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases
    Cefalu, William T.
    Andersen, Dana K.
    Arreaza-Rubin, Guillermo
    Pin, Christopher L.
    Sato, Sheryl
    Verchere, C. Bruce
    Woo, Minna
    Rosenblum, Norman D.
    CANADIAN JOURNAL OF DIABETES, 2021, 45 (08) : 697 - 713
  • [38] MERGING OF THE PEDIATRIC INTERAGENCY REGISTRY FOR MECHANICALLY ASSISTED CIRCULATORY SUPPORT (PEDIMACS) WITH AN EXYERNAL ADMINISTRATIVE DATABASE USING INDIRECT PATIENT IDENTIFIERS TO DEVELOP A MORE COMPREHENSIVE PLATFORM FOR HEALTH ECONOMICS AND OUTCOMES RESEARCH
    Dai, D.
    Huang, Y. H.
    Shamszad, P.
    Rossano, J. W.
    Cantor, R. S.
    Hall, M.
    Kirklin, J. K.
    VALUE IN HEALTH, 2018, 21 : S217 - S217
  • [39] Implement American Joint Commission on Cancer (AJCC) check-lists via the College of American Pathologist checklists (CAP-eCC) for structured data transmission to health records and analytic repositories in support of precision medicine
    Tuthill, J. M.
    Churchill, E.
    Younger, T.
    Brown, R.
    VIRCHOWS ARCHIV, 2018, 473 : S287 - S287